Session Type
Meeting
Search Results for CLOSTRIDIUM DIFFICILE
Plenary Presentations
Abstract Number: Plenary
SHM Converge 2021
Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent […]
Abstract Number: 9
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Hospital Onset Clostridium difficile infection (HOCDI) is one of the most common causes of hospital acquired diarrhea. As per a recent study, the mean healthcare costs attributable to primary Clostridium difficile infection (CDI) is about $24,205 per patient. This would be a lot more if the patients were to be discharged to skilled nursing […]
Abstract Number: 12
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Stony Brook University Hospital (SBUH) identified an opportunity to develop and implement prevention strategies to reduce hospital onset C. difficile infections (CDI). Hospital Onset (HO) CDI are included in National Healthcare Safety Network (NHSN) reporting and included with other hospital-acquired infections as publically reported data. CDI contribute to prolonged hospital stays, inappropriate antimicrobial use, […]
Abstract Number: 142
Hospital Medicine 2020, Virtual Competition
Background: In the United States, 32 million people have a documented penicillin allergy and up to 20% of hospitalized patients’ records describe a penicillin allergy (PcnA). Less than 10% of patients with reported penicillin allergy have true clinically relevant PcnA when objectively tested through rigorous skin testing (1-3). Clinicians subsequently avoid appropriate penicillin or penicillin […]
Abstract Number: 155
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: The overall incidence of Clostridium difficile infection (CDI) is higher among patients with inflammatory bowel disease (IBD). The nature of this disease association is unknown but likely involves an altered gut microbiome and impaired host immune responses. Studies on CDI in IBD patients have yielded variable and conflicting results on outcome measures such as […]
Abstract Number: 176
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Patients hospitalized with hematologic malignancy are particularly vulnerable to infection. Clostridium difficile infection (CDI) has become the most common cause of healthcare-associated infections in U. S. hospitals, and the excess healthcare costs related to CDI are estimated to be as much as 4. 8 billion dollars for acute care facilities alone. We sought to […]
Abstract Number: 190
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Data is emerging on the efficacy of fecal microbial transplantation (FMT) for recurrent clostridium difficile infection (CDI) management with success rates of 80-90% in general population. Immunocompromised patients continue to be excluded from randomized trials involving FMT due to concerns related to its safety and efficacy. Current guidelines recommend caution with FMT in immunocompromised […]
Abstract Number: 230
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Guidelines on the treatment of Clostridioides (Clostridium) difficile infection (CDI) have historically recommended avoiding antimotility agents (AAs) in patients with active CDI based on theoretical concerns that administration of AAs may precipitate serious adverse events such as toxic megacolon in these patients. These recommendations, however, are based on limited and conflicting data. We previously […]
Abstract Number: 265
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: There are 400,000 cases and 30,000 deaths from Clostridium difficile (C. diff) infections in the United States annually. Efforts to reduce the transmission of C. diff have focused on patients with diarrhea, however, many patients with C. diff are carriers who do not have symptoms. Because they are not isolated, carriers serve as a […]
Abstract Number: 266
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Timely Clostridium difficile Infection (CDI) testing is challenging but is important for faster and appropriate isolation and treatment of patients. Few studies have specifically addressed effective methods to hasten CDI testing without relying on PCR. We sought to use Quality Improvement methodologies including the Plan-Do-Study-Act (PDSA) Cycle and Control Charts to reduce CDI testing […]